*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. The Company's technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. It is developing COVAXIN, which is a whole-virion inactivated intramuscular COVID-19 vaccine candidate for the North American market. It is also developing a inhaled mucosal vaccine platform, which includes OCU500, a bivalent COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and bivalent COVID-19 vaccine. Its modifier gene therapy platform is focused on addressing various retinal diseases, including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), and Stargardt disease, with a single mutation-agnostic therapy.
|Yesterday's News, June 06, 2023|
|June 05, 2023|
Ocugen, Inc. Announces Business Advisory Board(Globe Newswire)
|June 02, 2023|
|June 01, 2023|
|May 31, 2023|
|May 30, 2023|
|May 26, 2023|
|May 25, 2023|
|May 24, 2023|
|May 23, 2023|
Ocugen, Inc. Announces Proposed Public Offering of Common Stock(Globe Newswire)
Ocugen to Present at BIO International Convention 2023(Globe Newswire)
|May 22, 2023|
|May 19, 2023|
|May 18, 2023|
|May 17, 2023|
|May 16, 2023|
|May 15, 2023|
Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.
Copyright © 2023. All rights reserved.